{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -4.66, "epsForward": -3.83, "epsCurrentYear": -3.62, "priceEpsCurrentYear": -19.441988, "sharesOutstanding": 43549200, "bookValue": 2.568, "fiftyDayAverage": 60.5208, "fiftyDayAverageChange": 9.859196, "fiftyDayAverageChangePercent": 0.1629059, "twoHundredDayAverage": 58.05475, "twoHundredDayAverageChange": 12.325249, "twoHundredDayAverageChangePercent": 0.21230389, "marketCap": 3064992512, "forwardPE": -18.375978, "priceToBook": 27.40654, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.9 - Buy", "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "USD", "regularMarketOpen": 70.54, "averageDailyVolume3Month": 36, "averageDailyVolume10Day": 36, "fiftyTwoWeekLowChange": 49.939995, "fiftyTwoWeekLowChangePercent": 2.4432483, "fiftyTwoWeekRange": "20.44 - 76.52", "fiftyTwoWeekHighChange": -6.1399994, "fiftyTwoWeekHighChangePercent": -0.08024046, "fiftyTwoWeekLow": 20.44, "fiftyTwoWeekHigh": 76.52, "earningsTimestamp": 1683547200, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1493013600000, "priceHint": 2, "marketState": "REGULAR", "regularMarketChange": -1.7800064, "regularMarketTime": 1683892036, "regularMarketDayHigh": 70.54, "regularMarketDayRange": "70.12 - 70.54", "regularMarketDayLow": 70.12, "regularMarketVolume": 300, "regularMarketPreviousClose": 72.16, "bid": 72.0, "ask": 72.18, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "regularMarketChangePercent": -2.4667494, "regularMarketPrice": 70.38, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "shortName": "AXSOME THERAPEUT. DL-0001", "longName": "Axsome Therapeutics, Inc.", "messageBoardId": "finmb_241907563", "market": "dr_market", "symbol": "19X.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "22 Cortlandt Street", "address2": "16th Floor", "city": "New York", "state": "NY", "zip": "10007", "country": "United States", "phone": "212 332 3241", "fax": "212 320 0245", "website": "https://www.axsome.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.", "fullTimeEmployees": 383, "companyOfficers": [{"maxAge": 1, "name": "Dr. Herriot  Tabuteau M.D.", "age": 54, "title": "Founder, Chairman, CEO & Pres", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 1320968, "fmt": "1.32M", "longFmt": "1,320,968"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 87923912, "fmt": "87.92M", "longFmt": "87,923,912"}}, {"maxAge": 1, "name": "Mr. Nick  Pizzie CPA, M.B.A.", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 732941, "fmt": "732.94k", "longFmt": "732,941"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 17865770, "fmt": "17.87M", "longFmt": "17,865,770"}}, {"maxAge": 1, "name": "Mr. Mark L. Jacobson", "age": 39, "title": "COO & Sec.", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": {"raw": 784661, "fmt": "784.66k", "longFmt": "784,661"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 28273134, "fmt": "28.27M", "longFmt": "28,273,134"}}, {"maxAge": 1, "name": "Mr. Hunter  Murdock Esq.", "age": 42, "title": "Gen. Counsel & Sec.", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 735388, "fmt": "735.39k", "longFmt": "735,388"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 909595, "fmt": "909.6k", "longFmt": "909,595"}}, {"maxAge": 1, "name": "Dr. Amanda  Jones Pharm.D.", "age": 39, "title": "Sr. VP of Clinical Devel.", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lori  Englebert M.B.A.", "age": 44, "title": "Exec. VP of Commercial & Bus. Devel.", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kevin  Laliberte Pharm.D.", "age": 44, "title": "Exec. VP of Product Strategy", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Joseph  Debrah-Afful CPA, M.B.A.", "title": "Director of Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}